U.S. pharma large copyright scrapped two experimental weight loss products previous 12 months—a as soon as-day by day pill, lotiglipron, as a result of elevated liver enzymes along with a twice-daily capsule, danuglipron, due to solid Unwanted side effects—but CEO Albert Bourla has stated the company is set to “Engage in and acquire” in the